Genentech, Inc.
NEWS
The U.S. Food and Drug Administration (FDA) approved Genentech’s Rituxan (rituximab) to treat adults with moderate to severe pemphigus vulgaris (PV).
The Biocom Institute and California Life Sciences Institute (CLSI) released their third biennial life science industry report. Overall, the report paints a very positive picture of the life science industry in California.
Genentech, a Roche company, and Microbiotica signed a multi-year strategic collaboration to discover, develop and commercialize biomarkers, targets and drugs for inflammatory bowel disease (IBD).
The 2018 BIO International Convention will be officially running from June 4 through June 7 and is celebrating 25 years of innovation.
Since 2009 May 30 has been set aside as a day to raise awareness and campaign for an end to multiple sclerosis. The theme this year is focused on the research being conducted to develop a cure for the neurological disease.
A combination of Genentech’s Tecentriq and chemotherapy enabled some lung cancer patients in a Phase III trial to live significantly longer than chemotherapy alone. The latest report continues the string of successes the company has had with Tecentriq, an anti-PD-L1 immunotherapy.
Genentech’s hemophilia treatment Hemlibra continues to demonstrate its efficacy in treating patients. New late-stage data presented at World Federation of Hemophilia 2018 World Congress shows the drug significantly reduced treated bleeds in a broad patient population in two separate studies.
Genentech, released follow-up data from its Phase III ALEX trial comparing its Alecensa (alectinib) to Pfizer’s Xalkori (crizotinib) in late-stage non-small cell lung cancer (NSCLC).
Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much.
JOBS
IN THE PRESS